Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENSURE-2: IMU-838 vs placebo in relapsing multiple sclerosis
2024-514619-88-00Phase 3Authorised
- Sponsor
- Immunic Therapeutics
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 14
01
Overview
Phase 3, randomised, double-blind trial of vidofludimus calcium in multiple sclerosis (MS) and secondary-progressive multiple sclerosis (SPMS) (3 arms), sponsored by Immunic Therapeutics. Primary endpoint: Time to first confirmed relapse. Planned start Oct 2024; status: authorised.
02
Drugs
vidofludimus calcium
03
Conditions
multiple sclerosis (MS)secondary-progressive multiple sclerosis (SPMS)
Beyond the preview
Go deeper on 2024-514619-88-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514619-88-00.